A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Trial Profile

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs TTI 621 (Primary) ; Nivolumab; Rituximab
  • Indications Acute lymphoblastic leukaemia; Haematological malignancies; Hodgkin's disease; Lymphoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Trillium Therapeutics
  • Most Recent Events

    • 19 Jun 2017 Protocol amended with inclusion of patients with solid tumor, change in study design, treatment arm and primary end point revised.
    • 19 Jun 2017 Planned number of patients changed from 186 to 270.
    • 07 Jun 2017 According to a Trillium Therapeutics Inc media release, this trial has been expanded to include an additional cohort of patients with Hodgkin lymphoma treated with combination of TTI-621 and nivolumab and two additional cohorts of patients with T and B-cell AML and small cell lung cancer treated with TTO-621 monotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top